The Institute for Clinical and Economic Review (ICER) is partnering with the BHC to launch the Midwest Comparative Effectiveness Public Advisory Council (CEPAC). The group will convene three times a year with public meetings to discuss ICER evidence reports, gather input on policy implications from stakeholders, and vote upon the strength of evidence on the effectiveness and value of new drugs. The group will also help frame recommendations for how the existing evidence can best be interpreted to guide clinical practice and coverage policy. ICER is currently recruiting members for the Midwest CEPAC that represent a wide variety of backgrounds, specialties and perspectives, and come from Midwest states. To learn more about recruitment for the Midwest CEPAC, click here.